MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326919 | Name: Acoziborole
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acoziborole, also known as SCYX-7158 is an orally-active compound with potent antitrypanosoma activity for the potent treatment of stage 2 human African trypanosomiasis. Human African trypanosomiasis (HAT, better called as sleeping sickness), caused by two morphologically identicalprotozoan parasite Trypanosoma bruceiis transmitted by the bite of tsetse flies of Glossinagenus, mainly in the rural areas of the sub-Saharan Africa.

Chemical Structure

Acoziborole
Acoziborole
CAS#1266084-51-8

Theoretical Analysis

MedKoo Cat#: 326919

Name: Acoziborole

CAS#: 1266084-51-8

Chemical Formula: C17H14BF4NO3

Exact Mass: 367.1003

Molecular Weight: 367.11

Elemental Analysis: C, 55.62; H, 3.84; B, 2.94; F, 20.70; N, 3.82; O, 13.07

Price and Availability

Size Price Availability Quantity
100mg USD 650.00 2 Weeks
250mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SCYX-7158; SCYX7158; SCYX 7158; Oxaborole; Acoziborole.
IUPAC/Chemical Name
4-fluoro-N-(1-hydroxy-3,3-dimethyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-(trifluoromethyl)benzamide
InChi Key
PTYGDEXEGLDNAZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H14BF4NO3/c1-16(2)12-6-4-10(8-14(12)18(25)26-16)23-15(24)11-5-3-9(19)7-13(11)17(20,21)22/h3-8,25H,1-2H3,(H,23,24)
SMILES Code
FC1=CC(C(F)(F)F)=C(C(NC2=CC=C(C(C)(C)OB3O)C3=C2)=O)C=C1
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 367.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kennedy PGE. Update on human African trypanosomiasis (sleeping sickness). J Neurol. 2019 Sep;266(9):2334-2337. doi: 10.1007/s00415-019-09425-7. Epub 2019 Jun 17. PMID: 31209574. 2: Meyer KJ, Meyers DJ, Shapiro TA. Optimal kinetic exposures for classic and candidate antitrypanosomals. J Antimicrob Chemother. 2019 Aug 1;74(8):2303-2310. doi: 10.1093/jac/dkz160. PMID: 31093674; PMCID: PMC6640303. 3: Wall RJ, Rico E, Lukac I, Zuccotto F, Elg S, Gilbert IH, Freund Y, Alley MRK, Field MC, Wyllie S, Horn D. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9616-9621. doi: 10.1073/pnas.1807915115. Epub 2018 Sep 5. PMID: 30185555; PMCID: PMC6156652. 4: Steketee PC, Vincent IM, Achcar F, Giordani F, Kim DH, Creek DJ, Freund Y, Jacobs R, Rattigan K, Horn D, Field MC, MacLeod A, Barrett MP. Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. PLoS Negl Trop Dis. 2018 May 14;12(5):e0006450. doi: 10.1371/journal.pntd.0006450. PMID: 29758036; PMCID: PMC5976210. 5: Njouendou AJ, Fombad FF, O'Neill M, Zofou D, Nutting C, Ndongmo PC, Kengne- Ouafo AJ, Geary TG, Mackenzie CD, Wanji S. Heterogeneity in the in vitro susceptibility of Loa loa microfilariae to drugs commonly used in parasitological infections. Parasit Vectors. 2018 Apr 4;11(1):223. doi: 10.1186/s13071-018-2799-3. PMID: 29615094; PMCID: PMC5883330. 6: Maxmen A. Busting the billion-dollar myth: how to slash the cost of drug development. Nature. 2016 Aug 25;536(7617):388-90. doi: 10.1038/536388a. PMID: 27558048. 7: Singh Grewal A, Pandita D, Bhardwaj S, Lather V. Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis. Curr Top Med Chem. 2016;16(20):2245-65. doi: 10.2174/1568026616666160413125335. PMID: 27072715. 8: Jones DC, Foth BJ, Urbaniak MD, Patterson S, Ong HB, Berriman M, Fairlamb AH. Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome. PLoS Negl Trop Dis. 2015 Dec 18;9(12):e0004299. doi: 10.1371/journal.pntd.0004299. PMID: 26684831; PMCID: PMC4689576. 9: Eperon G, Balasegaram M, Potet J, Mowbray C, Valverde O, Chappuis F. Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther. 2014 Nov;12(11):1407-17. doi: 10.1586/14787210.2014.959496. Epub 2014 Sep 10. PMID: 25204360; PMCID: PMC4743611. 10: Wring S, Gaukel E, Nare B, Jacobs R, Beaudet B, Bowling T, Mercer L, Bacchi C, Yarlett N, Randolph R, Parham R, Rewerts C, Platner J, Don R. Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis. Parasitology. 2014 Jan;141(1):104-18. doi: 10.1017/S003118201300098X. Epub 2013 Sep 5. PMID: 24007596; PMCID: PMC3884839. 11: Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104(1):175-96. doi: 10.1093/bmb/lds031. Epub 2012 Nov 7. PMID: 23137768; PMCID: PMC3530408. 12: Mäser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, Brun R. Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol. 2012 Oct;12(5):562-6. doi: 10.1016/j.coph.2012.05.001. Epub 2012 May 29. PMID: 22652215. 13: Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, Gaukel EG, Orr MD, Perales JB, Jenks M, Noe RA, Sligar JM, Zhang YK, Bacchi CJ, Yarlett N, Don R. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem. 2011 Aug;3(10):1259-78. doi: 10.4155/fmc.11.80. PMID: 21859301. 14: Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, Sligar JM, Jenks MX, Noe RA, Bowling TS, Mercer LT, Rewerts C, Gaukel E, Owens J, Parham R, Randolph R, Beaudet B, Bacchi CJ, Yarlett N, Plattner JJ, Freund Y, Ding C, Akama T, Zhang YK, Brun R, Kaiser M, Scandale I, Don R. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. doi: 10.1371/journal.pntd.0001151. Epub 2011 Jun 28. PMID: 21738803; PMCID: PMC3125149. 15: Barrett MP. Potential new drugs for human African trypanosomiasis: some progress at last. Curr Opin Infect Dis. 2010 Dec;23(6):603-8. doi: 10.1097/QCO.0b013e32833f9fd0. PMID: 20844428.